Drug Trial Radar · NCT06422117
Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China
Last checked: Nov 20, 2026Latest source record: May 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
408
Planned (sponsor's estimate)
Start
May 30, 2024
Primary completion
Jul 30, 2027
Study completion Aug 7, 2027
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.
Conditions
- Central Neuropathic Pain
Interventions
HSK16149 20mg-40mg BIDDrug
Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
PlaceboDrug
Placebo, oral, 2 capsules twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The changes of pain scores after treatment in HSK16149 group and placebo group were compared with baselineTime frame: week12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.